aTyr Pharma (NASDAQ:LIFE) Posts Quarterly Earnings Results, Beats Expectations By $0.94 EPS
aTyr Pharma (NASDAQ:LIFE) announced its earnings results on Wednesday. The biotechnology company reported ($1.80) EPS for the quarter, beating the consensus estimate of ($2.74) by $0.94, Morningstar.com reports. The business had revenue of $0.09 million for the quarter.
LIFE stock traded up $0.07 during trading on Thursday, reaching $2.87. 905 shares of the stock were exchanged, compared to its average volume of 159,297. The business’s 50 day simple moving average is $3.67. aTyr Pharma has a twelve month low of $2.80 and a twelve month high of $12.32. The company has a debt-to-equity ratio of 0.31, a quick ratio of 4.00 and a current ratio of 4.00.
Separately, ValuEngine upgraded aTyr Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, July 2nd. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. aTyr Pharma currently has a consensus rating of “Buy” and a consensus target price of $14.18.
aTyr Pharma Company Profile
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD.
Featured Article: What does it mean to hold a stock in street name?
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.